Most-Downgraded StocksMost-DowngradedNASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ACAD Stock Alerts $16.31 -0.28 (-1.69%) (As of 04:31 PM ET) Add Compare Share Share Today's Range$16.16▼$16.5150-Day Range$16.59▼$26.3652-Week Range$16.16▼$33.99Volume1.63 million shsAverage Volume1.77 million shsMarket Capitalization$2.69 billionP/E RatioN/ADividend YieldN/APrice Target$35.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ACADIA Pharmaceuticals alerts: Email Address ACADIA Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside119.8% Upside$35.82 Price TargetShort InterestBearish6.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.20Based on 10 Articles This WeekInsider TradingSelling Shares$1.29 M Sold Last QuarterProj. Earnings Growth88.71%From $0.62 to $1.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.80 out of 5 starsMedical Sector261st out of 907 stocksPharmaceutical Preparations Industry110th out of 422 stocks 4.4 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.77% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 0.36%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 1.0 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for ACADIA Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 9 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -23% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,291,362.00 in company stock.Percentage Held by Insiders27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 88.71% in the coming year, from $0.62 to $1.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -42.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -42.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More ACAD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesApril 10, 2024 | insidertrades.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider James Kihara Sells 1,790 SharesMarch 29, 2024 | insidertrades.comInsider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) COO Sells 5,140 Shares of StockApril 25, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 24, 2024 | businesswire.comAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024April 24, 2024 | americanbankingnews.comFY2025 EPS Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreased by AnalystApril 22, 2024 | businesswire.comAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health CanadaApril 19, 2024 | businesswire.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 18, 2024 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week Low at $16.60April 25, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.April 17, 2024 | businesswire.comAcadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual MeetingApril 16, 2024 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Up 5.4% in MarchApril 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)April 12, 2024 | stocknews.com3 Affordable Pharma Stocks to Buy for Portfolio GainsApril 11, 2024 | investing.comAcadia Pharmaceuticals executive sells over $31,000 in company stockApril 11, 2024 | investing.comAcadia Pharmaceuticals exec sells over $45k in stockApril 11, 2024 | investorplace.com3 Pharma Stocks to Sell in April Before They Crash & BurnApril 11, 2024 | markets.businessinsider.comBuy Rating Justified by Vertex Pharmaceuticals’ Strategic Acquisitions and Promising Drug PipelineApril 10, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For ACADIA PharmaceuticalsApril 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)April 4, 2024 | investing.comAcadia Pharmaceuticals names new EVP of Research and DevelopmentApril 1, 2024 | finance.yahoo.comAcadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Syros Pharmaceuticals Amid Promising Clinical Trials and Strategic Study DesignsMarch 28, 2024 | uk.investing.comThese Overlooked Mid-Cap Gems Are Ripe for a ReboundMarch 28, 2024 | finance.yahoo.comACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 SharesMarch 25, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)March 19, 2024 | stocknews.com4 Cutting-Edge Pharma Stocks for Portfolio DiversificationMarch 18, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Edwards Lifesciences (EW) and Aveanna Healthcare Holdings (AVAH)See More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/25/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees597Year FoundedN/APrice Target and Rating Average Stock Price Target$35.82 High Stock Price Target$95.00 Low Stock Price Target$25.00 Potential Upside/Downside+119.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E Ratio26.34 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins-8.44% Pretax Margin-7.03% Return on Equity-15.67% Return on Assets-9.15% Debt Debt-to-Equity RatioN/A Current Ratio2.42 Quick Ratio2.28 Sales & Book Value Annual Sales$726.44 million Price / Sales3.70 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book6.21Miscellaneous Outstanding Shares164,770,000Free Float119,460,000Market Cap$2.69 billion OptionableOptionable Beta0.37 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 63)President, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Executive VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 55)Executive VP, COO & Head of Commercial Comp: $724.31kMr. James K. Kihara (Age 43)VP, Chief Accounting Officer & Corporate Controller Mr. Benir RuanoSenior Vice President of Technical Development & OperationsMr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsMs. Jennifer J. Rhodes J.D. (Age 54)Executive VP, Chief Legal Officer & Secretary Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyMs. Holly ValdiviezSenior VP & Head of SalesMr. Rob AcklesSenior VP & Chief People OfficerMore ExecutivesKey CompetitorsMoonLake ImmunotherapeuticsNASDAQ:MLTXMorphoSysNASDAQ:MOREvotecNASDAQ:EVOSummit TherapeuticsNASDAQ:SMMTIDEAYA BiosciencesNASDAQ:IDYAView All CompetitorsInsiders & InstitutionsRice Hall James & Associates LLCSold 28,296 shares on 4/23/2024Ownership: 0.403%Wesbanco Bank Inc.Bought 26,800 shares on 4/23/2024Ownership: 0.016%Allspring Global Investments Holdings LLCSold 88,253 shares on 4/18/2024Ownership: 0.036%Diversified Trust CoBought 1,826 shares on 4/18/2024Ownership: 0.019%Hennion & Walsh Asset Management Inc.Bought 27,871 shares on 4/17/2024Ownership: 0.087%View All Insider TransactionsView All Institutional Transactions ACAD Stock Analysis - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price target for 2024? 15 equities research analysts have issued 1 year price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price targets range from $25.00 to $95.00. On average, they predict the company's share price to reach $35.82 in the next twelve months. This suggests a possible upside of 119.8% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2024? ACADIA Pharmaceuticals' stock was trading at $31.31 at the beginning of 2024. Since then, ACAD stock has decreased by 47.9% and is now trading at $16.30. View the best growth stocks for 2024 here. Are investors shorting ACADIA Pharmaceuticals? ACADIA Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 11,200,000 shares, an increase of 5.4% from the March 15th total of 10,630,000 shares. Based on an average trading volume of 1,830,000 shares, the short-interest ratio is presently 6.1 days. View ACADIA Pharmaceuticals' Short Interest. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing analysts' consensus estimates of $0.32 by $0.04. The biopharmaceutical company earned $231.04 million during the quarter, compared to the consensus estimate of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative trailing twelve-month return on equity of 15.67%. The business's quarterly revenue was up 69.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include Alger Weatherbie Enduring Growth ETF (AWEG), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO) and Virtus LifeSci Biotech Products ETF (BBP).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $930.0 million-$1.0 billion, compared to the consensus revenue estimate of $965.1 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.40%), Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%), Allspring Global Investments Holdings LLC (0.04%), Diversified Trust Co (0.02%) and Wesbanco Bank Inc. (0.02%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, Laura Brege, Mark C Schneyer, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACAD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
